Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Vera Therapeutics
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 5, 2026
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
June 2, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 29, 2026
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
May 28, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2026
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
May 22, 2026
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
May 17, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2026
Vera Therapeutics Appoints Christopher Hite to Board of Directors
May 16, 2026
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
January 28, 2026